These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30371180)

  • 1. Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA.
    Almahmoud MF; Soliman EZ; Bertoni AG; Kestenbaum B; Katz R; Lima JAC; Ouyang P; Miller PE; Michos ED; Herrington DM
    J Am Heart Assoc; 2018 Sep; 7(18):e008334. PubMed ID: 30371180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction.
    Koller L; Kleber ME; Brandenburg VM; Goliasch G; Richter B; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; Berger R; Mörtl D; Hülsmann M; Pacher R; März W; Niessner A
    Circ Heart Fail; 2015 Nov; 8(6):1059-67. PubMed ID: 26273098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular dilation and incident congestive heart failure in asymptomatic adults without cardiovascular disease: multi-ethnic study of atherosclerosis (MESA).
    Yeboah J; Bluemke DA; Hundley WG; Rodriguez CJ; Lima JA; Herrington DM
    J Card Fail; 2014 Dec; 20(12):905-11. PubMed ID: 25225112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network.
    Fudim M; Ambrosy AP; Sun JL; Anstrom KJ; Bart BA; Butler J; AbouEzzeddine O; Greene SJ; Mentz RJ; Redfield MM; Reddy YNV; Vaduganathan M; Braunwald E; Hernandez AF; Borlaug BA; Felker GM
    J Am Heart Assoc; 2018 Dec; 7(24):e010364. PubMed ID: 30561266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ankle-brachial index and incident heart failure with reduced versus preserved ejection fraction: The Multi-Ethnic Study of Atherosclerosis.
    Prasada S; Shah SJ; Michos ED; Polak JF; Greenland P
    Vasc Med; 2019 Dec; 24(6):501-510. PubMed ID: 31480898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Risk for Incident Heart Failure With Omega-3 Fatty Acids: From MESA.
    Block RC; Liu L; Herrington DM; Huang S; Tsai MY; O'Connell TD; Shearer GC
    JACC Heart Fail; 2019 Aug; 7(8):651-661. PubMed ID: 31302044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction.
    Roy C; Lejeune S; Slimani A; de Meester C; Ahn As SA; Rousseau MF; Mihaela A; Ginion A; Ferracin B; Pasquet A; Vancraeynest D; Beauloye C; Vanoverschelde JL; Horman S; Gruson D; Gerber BL; Pouleur AC
    ESC Heart Fail; 2020 Oct; 7(5):2494-2507. PubMed ID: 32578967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction.
    Lin TK; Hsu BC; Li YD; Chen CH; Lin JW; Chien CY; Weng CY
    J Am Heart Assoc; 2019 Jun; 8(12):e010739. PubMed ID: 31181979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resting heart rate as predictor for left ventricular dysfunction and heart failure: MESA (Multi-Ethnic Study of Atherosclerosis).
    Opdahl A; Ambale Venkatesh B; Fernandes VRS; Wu CO; Nasir K; Choi EY; Almeida ALC; Rosen B; Carvalho B; Edvardsen T; Bluemke DA; Lima JAC
    J Am Coll Cardiol; 2014 Apr; 63(12):1182-1189. PubMed ID: 24412444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure.
    Chirinos JA; Sardana M; Oldland G; Ansari B; Lee J; Hussain A; Mustafa A; Akers SR; Wei W; Lakatta EG; Fedorova OV
    ESC Heart Fail; 2018 Oct; 5(5):911-919. PubMed ID: 29969536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach.
    Hage C; Michaëlsson E; Linde C; Donal E; Daubert JC; Gan LM; Lund LH
    Circ Cardiovasc Genet; 2017 Feb; 10(1):. PubMed ID: 28100627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study.
    Binnenmars SH; Hoogslag GE; Yeung SMH; Brouwers FP; Bakker SJL; van Gilst WH; Gansevoort RT; Navis G; Voors AA; de Borst MH
    J Am Heart Assoc; 2022 Aug; 11(15):e024952. PubMed ID: 35876420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of circulating fibroblast growth factor 21 levels with incident heart failure: The Multi-Ethnic Study of Atherosclerosis.
    Tucker W; McClelland RL; Allison MA; Szklo M; Rye KA; Ong KL
    Metabolism; 2023 Jun; 143():155535. PubMed ID: 36931558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease.
    Imazu M; Takahama H; Asanuma H; Funada A; Sugano Y; Ohara T; Hasegawa T; Asakura M; Kanzaki H; Anzai T; Kitakaze M
    Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1504-11. PubMed ID: 25217649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left Atrial Phasic Function by Cardiac Magnetic Resonance Feature Tracking Is a Strong Predictor of Incident Cardiovascular Events.
    Chirinos JA; Sardana M; Ansari B; Satija V; Kuriakose D; Edelstein I; Oldland G; Miller R; Gaddam S; Lee J; Suri A; Akers SR
    Circ Cardiovasc Imaging; 2018 Dec; 11(12):e007512. PubMed ID: 30562112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul Study.
    Welles CC; Ku IA; Kwan DM; Whooley MA; Schiller NB; Turakhia MP
    J Am Coll Cardiol; 2012 Feb; 59(7):673-80. PubMed ID: 22322084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory pathways in patients with heart failure and preserved ejection fraction.
    Niethammer M; Sieber M; von Haehling S; Anker SD; Munzel T; Horstick G; Genth-Zotz S
    Int J Cardiol; 2008 Sep; 129(1):111-7. PubMed ID: 17658631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterial Stiffness and Risk of Overall Heart Failure, Heart Failure With Preserved Ejection Fraction, and Heart Failure With Reduced Ejection Fraction: The Health ABC Study (Health, Aging, and Body Composition).
    Pandey A; Khan H; Newman AB; Lakatta EG; Forman DE; Butler J; Berry JD
    Hypertension; 2017 Feb; 69(2):267-274. PubMed ID: 27993954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis.
    Jang S; Ogunmoroti O; Ndumele CE; Zhao D; Rao VN; Fashanu OE; Tibuakuu M; Otvos JD; Benson EM; Ouyang P; Michos ED
    Circ Heart Fail; 2020 Aug; 13(8):e007067. PubMed ID: 32762458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.